Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstraße 21-23, 91054, Erlangen, Germany.
Department of Obstetrics and Gynecology, Hospital of Aschaffenburg-Alzenau, Aschaffenburg, Germany.
Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
Growing demand for risk-reducing surgery in individuals with inherited susceptibility to cancer leads to the question whether these procedures are cost effective for the executing hospitals. This study compared the clinical costs for bilateral risk-reducing mastectomy (BRRM) with and without different types of reconstruction, risk-reducing salpingo-oophorectomy (RRSO), and their combinations with corresponding reimbursements in the statutory health-care system in Germany.
Real total costs of care for BRRM with and without reconstruction, RRSO, and their combinations were calculated as the sum of all personnel and technical costs. These costs calculated in a German University hospital were compared with the sum of all reimbursements in the German DRG-based health-care system.
While sole RRSO, BRRM without reconstruction, and BRRM with secondary DIEP (deep inferior epigastric perforator)-reconstruction still result in a small benefit, we even found shortfalls for the hospital with all other prophylactic operations under consideration. The calculated deficits were especially high for BRRM with implant-based breast reconstruction and for combined operations when the risk reduction is achieved with a minimum of separate operations.
Risk-reducing surgery in BRCA-mutation carriers is frequently not cost-covering for the executing hospitals in the German health-care system. Thus, appropriate concepts are required to ensure a nationwide care.
遗传性癌症易感性个体对降低风险手术的需求不断增长,这引发了一个问题,即这些手术对执行医院是否具有成本效益。本研究比较了德国法定医疗保险体系中双侧预防性乳房切除术(BRRM)、不同类型重建术、预防性输卵管卵巢切除术(RRSO)及其组合的临床成本与其相应的报销费用。
BRRM 有无重建、RRSO 及其组合的实际总护理成本计算为所有人员和技术成本的总和。在德国一家大学医院计算的这些成本与德国基于 DRG 的医疗保险体系的所有报销费用总和进行了比较。
尽管单独 RRSO、无重建的 BRRM 和继发性 DIEP(腹壁下动脉穿支)重建的 BRRM 仍有一定获益,但对于考虑到所有其他预防性手术的医院,我们甚至发现存在亏损。对于采用植入物乳房重建的 BRRM 和风险降低仅通过最少的单独手术实现的联合手术,计算出的亏损尤其高。
在德国医疗保健系统中,BRCA 基因突变携带者的降低风险手术通常不能为执行医院带来收益。因此,需要制定适当的概念来确保全国范围内的护理。